Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/15638
Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication
Identifiers
ISSN: 1174-5886
eISSN: 1179-6901
WOS ID: 000435093100003
Scopus EID: 2-s2.0-85044343198
PMID: 29572732
Embase PUI: L621401685
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordPublication date
2018-06Document type
research articleCitation
Guitart J, Vargas MI, De Sanctis V, Folch J, Salazar R, Fuentes J, et al. Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication. Drugs R&D. 2018 Jun;18(2):119-28.Abstract
Objective Our objective was to assess the effect of sublingual fentanyl tablets (SFTs) on pain relief, quality of life, and adverse effects in patients with cancer pain, according to cancer stage and background opioid regimen. Methods Subgroup analyses from a recently completed study were performed according to cancer stage (locally advanced cancer [LAC] vs. metastatic cancer) and most frequent background opioid medication (fentanyl vs. oxycodone/naloxone). The efficacy and safety of SFTs were evaluated, recording pain intensity (PI), onset of pain relief, and adverse events (AEs). Health status was assessed with the Short Form 12, version 2 (SF-12v2) questionnaire and the Hospital Anxiety and Depression Scale (anxiety subscale [HADS-A] and depression subscale [HADS-D]). Results In total, 54 (67.5%) patients had LAC and 26 (32.5%) had metastatic cancer. The oxycodone/naloxone group included 39 patients (48.1%) and the fentanyl group 29 (35.8%). In all subgroups, pain relief was achieved within 5 min in an increasing number of individuals over time; at the end of the study, PI values decreased (PI-end: 44.4% for LAC vs. 57.9% for metastatic cancer; 44.4% for fentanyl vs. 38.6% for oxycodone/naloxone). HADS and mental component summary (MCS) SF-12v2 scores significantly improved in the LAC group (HADS-A 9.44-8.04; HADS-D 10.46-8.15; MCS 44.69-45.94) and in the fentanyl group (HADS-A 10.05-8.33; HADS-D 11.95-8.76; MCS 44.38-47.19). AEs were reported in few patients and were mostly mild. Conclusions Exploratory subgroup analyses show the efficacy and safety of SFTs for the treatment of breakthrough pain in patients with cancer, regardless of their cancer stage and background opioid medication.
Publisher version
https://dx.doi.org/10.1007/s40268-018-0231-2MeSH
AgedDrug Combinations
Analgesics, Opioid
Humans
Drug Therapy, Combination
Neoplasms
Administration, Sublingual
Breakthrough Pain
Neoplasm Staging
Fentanyl
Male
Quality of Life
Female
Treatment Outcome
Naloxone
Pain Management
Oxycodone
DeCS
NaloxonaDolor Irruptivo
Resultado del Tratamiento
Fentanilo
Femenino
Estadificación de Neoplasias
Masculino
Manejo del Dolor
Administración Sublingual
Quimioterapia Combinada
Combinación de Medicamentos
Humanos
Neoplasias
Calidad de Vida
Anciano
Analgésicos Opioides
Oxicodona
This item appears in following Docusalut collections
Hospital Comarcal de Inca - HCIN > Comunicación científicaÁrea de Salud de Menorca - ASME > Comunicación científica